Loading
Extensive Stage Lung Small Cell Cancer / Tarlatamab · Phase 2 Trial
ClinicalTrials.gov · August 19, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registry record for START-lung, an ongoing international phase 2 single-arm trial of tarlatamab in pretreated ES-SCLC patients with ECOG PS 2. No results are posted in this registry entry. The study aims to assess 12-month overall survival as the primary outcome, with recruitment active and follow-up planned for approximately 41 months.
Phase 2, Interventional, Single Group, Open label, Treatment purpose. Extensive Stage Lung Small Cell Cancer; age from 18 Years. Intervention: Tarlatamab. n = 48. 19 sites across 5 countries.
This is a registry record for START-lung, an ongoing international phase 2 single-arm trial of tarlatamab in pretreated ES-SCLC patients with ECOG PS 2. No results are posted in this registry entry. The study aims to assess 12-month overall survival as the primary outcome, with recruitment active and follow-up planned for approximately 41 months.
Response rates, progression-free survival, and safety profile not reported in registry entry.
This record describes a trial still recruiting with no interim or final results available. Clinicians should await publication of efficacy and safety data before considering implications for ECOG PS 2 patients with pretreated ES-SCLC.
This is a registry record of an ongoing Phase 2 single-arm trial with no results posted; it describes planned conduct and endpoints only.
As stated by the source record.
Quoted from the source exactly as published.
This record describes a trial still recruiting with no interim or final results available. Clinicians should await publication of efficacy and safety data before considering implications for ECOG PS 2 patients with pretreated ES-SCLC.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07203053). This is a study registration, not published results. Lead sponsor: ETOP IBCSG Partners Foundation. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 48 participants (ESTIMATED). Conditions: Extensive Stage Lung Small Cell Cancer. Interventions: DRUG: Tarlatamab. Primary outcome measures: Overall survival rate at 12 months (12-month OS) , OS is defined as the time from the date of enrolment until death from any cause. Assessed for approximately up to 41 months.. Brief summary: START-lung is an international, multicentre, single-arm phase II trial. Protocol treatment consists of tarlatamab administered as an intravenous infusion until disease progression according to RECIST v1.1 criteria, unacceptable toxicity, or patient decision, whichever comes first. The primary objective of the trial is to assess the clinical efficacy of tarlatamab, in terms of 12-month OS rate, in patients with ES-SCLC and ECOG PS 2 who have previously received only one line of platinum-etoposide doublet chemotherapy with immune-checkpoint inhibition and whose disease has progressed.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.